Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative, Oncological, and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DYRK1A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | DYRK1A Active Kinase Protein (1-498 aa) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View DYRK1A Products |
| Antigen (Mutant) | DYRK1A Gatekeeper Mutant (F238L) & Activation Loop Mutant. Engineered for resistance profiling. Endotoxin <1EU/ug. | View DYRK1A Products |
| Gene Delivery | DYRK1A Promise-ORF / Lentivirus Full-length ORF with N-terminal FLAG for stable cell line construction. | View DYRK1A Products |
| Benchmark Ab | Anti-DYRK1A Benchmark Antibody. Recombinant positive control for western blot and screening. | View DYRK1A Products |
| Validator | DYRK1A siRNA Set (3 unique sequences). For knockdown verification and assay specificity confirmation. | View DYRK1A Products |
| Related Target: DYRK1B | DYRK1B Kinase Domain Protein. Close paralog (84% identity) for off-target screening. High Purity (>95%). | View DYRK1B Products |
| Related Target: CLK1 | CLK1 Protein. Structurally related kinase for off-target evaluation. | View CLK1 Products |
| Related Target: GSK3B | GSK3B Kinase Protein. Synergistic tau kinase for combination screening and pathway analysis. | View GSK3B Products |
| Related Target: MAPT | Tau (MAPT) Recombinant Protein. Primary substrate for phosphorylation assays (T212/Ser400 sites). | View MAPT Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Selectivity (DYRK Family & CLK) | Homolog panel proteins (DYRK1B, CLK1) strictly verified by mass spec and sequence analysis. Paralog-specific N-terminal regions for orthogonal cascades. |
| Reproducibility in HTS Assays | High-purity (>95%) recombinant kinase expressed in optimization-controlled systems for theoretical MW precision. |
| Lack of Reliable Pathway Controls | Clinical Benchmark Antibodies included for precise assay calibration. Recombinant monoclonal antibodies for Western/IP. |
| False Positives in Cellular Models | Sequence-verified siRNA included for rigorous specificity and knockdown checks. |
| Cellular Target Engagement (pTau reduction) | High-titer Lentivirus (>10^8 TU/mL) for stable overexpression; Compatible with high-content imaging for phosphorylated Tau readouts. |
| Resistance Mutation Profiling | Gatekeeper (F238L) and Activation Loop mutants available; Sequence verified mutations for resistance mechanism studies. |
Live DYRK1A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Inhibitor Research
- ➤ Latest Resistance Research
- ➤ Resistance Mechanism Studies
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for DYRK1A therapeutics is intensifying, with major players shifting focus toward highly selective small molecule inhibitors. As a dual-specificity kinase located on chromosome 21, DYRK1A is deeply implicated in Down syndrome cognitive deficits, Alzheimer's disease (tau phosphorylation), metabolic disorders (pancreatic beta-cell proliferation), and hematological malignancies. First-generation molecules (e.g., EHT 1610, INDY derivatives) are advancing to Phase I/II. The next wave of R&D targets unprecedented kinase selectivity, optimized Blood-Brain Barrier (BBB) penetrance for CNS indications, allosteric inhibition strategies, and targeted degradation approaches (PROTAC) to overcome selectivity and resistance challenges.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor (ATP-competitive) | ManRos Therapeutics, NeuroNascent, Anavex, Daiichi Sankyo | Alzheimer's, Down Syndrome, AML | Kinase Selectivity Assay (Need high-purity Homolog Proteins for IC50 determination) |
| Small Molecule (Regenerative) | GNF (Novartis), JDRF | Type 1 / Type 2 Diabetes | Beta-cell Proliferation Assay (Need strictly controlled Endotoxin levels) |
| Small Molecule (Allosteric) | Emerging biotechs | Acute Myeloid Leukemia | Conformation-specific Binding Assays (Need mutant proteins for allosteric site mapping) |
| Peptide/Protein Inhibitor | Preclinical stage | Neuroprotection | Target Engagement Assays (Need high-purity substrate proteins like Tau for phosphorylation inhibition) |
| Degrader (PROTAC) | Academic / Early Biotech | Oncology (Glioblastoma, Solid Tumors) | Cellular Degradation Assays (Need stable cell lines via lentiviral delivery; ternary complex validation with native-conformation proteins) |
Strategic Implications for Drug Developers
Achieving best-in-class DYRK1A therapeutics requires differentiation in three dimensions: (1) Kinase Selectivity: Must achieve >50-100 fold selectivity over DYRK1B and CLK families using cross-screening panels; (2) Delivery & Distribution: For CNS, optimize BBB penetration (LogP<2, MW<400); for diabetes, restrict CNS exposure. TarMart provides high-purity lentivirus for cellular target engagement assays and benchmark antibodies for pharmacodynamic readouts (e.g., pTau levels). (3) Resistance Profiling: Prepare for gatekeeper mutations (F238L) using mutant protein panels. TarMart's rationally designed recombinant proteins support both biochemical IC50 determination and cellular degradation assays, enabling robust resistance barrier assessment.